抗病毒治疗对乙型肝炎相关慢加急性肝衰竭近期及远期疗效的影响

目的回顾性分析抗病毒治疗对乙型肝炎相关慢加急性肝衰竭近期及远期疗效的影响。方法 51例乙型肝炎相关慢加急性肝衰竭病例,按有无应用抗病毒药物分为抗病毒组和未抗病毒组,查阅住院期间的病例并记录随访5年内的资料,比较两者之间近期及远期疗效的差别。结果近期疗效比较：抗病毒组和未抗病毒组出院时好转率分别为70.00%和36.36%,两者之间差异有统计学意义（P〈0.05）。远期疗效比较：抗病毒组12、36和60个月累积生存率分别为76.40%、72.10%和72.10%;未抗病毒组12、36和60个月累积生存率分别为36.36%、27.30%和27.30%,两者之间差异有统计学意义（P〈0.05）。结论抗病毒治疗可明显改善乙型肝炎相关慢加急性肝衰竭患者的预后,提高生存率,延长存活时间。

Short-term and long-term efficacy of antiviral treatment of patients with HBV-associated acute-on-chronic liver failure

Objective To analyze the impact of antiviral therapy on short-term and long-term prognosis of patients with hepatitis B virus-associated acute-on-chronic liver failure（HBV-ACLF） in a retrospective study.Methods A total of 51 patients with HBV-ACLF who had been treated with antiviral drugs（antiviral group） and who did not receive antiviral therapy（non-antiviral group） were retrospectively analyzed.The medical records from in-hospital treatment and five years of follow-up were comparatively analyzed for the two groups to assess differences in patient outcome and determine the clinical benefit associated with antiviral therapy.Results The recovery rate at hospital discharge was significantly higher for patients in the antiviral group（70.00% vs.non-antiviral group：36.36%,P0.05）.In addition,the cumulative survival rates were significantly higher for the antiviral group during follow-up at 12,36 and 60 months（antiviral group vs.non-antiviral group：76.40% vs.36.36%,72.10% vs.27.30%,and vs.27.30%;all P0.05）.Conclusion Antiviral therapy can significantly improve prognosis and survival rate,as well as time to death,of HBV-ACLF patients.